Towards single-tablet therapy for type 2 diabetes mellitus. Rationale and recent developments

Area of Science:

• Endocrinology
• Pharmacology
• Metabolic Diseases

Background:

• Type 2 diabetes mellitus (T2DM) involves complex pathophysiology, including insulin deficiency and resistance.
• Tailoring pharmacotherapy to T2DM pathophysiology requires agents with complementary mechanisms of action.

Purpose of the Study:

• To evaluate the efficacy and safety of fixed-dose combination antihyperglycemic agents for T2DM management.
• To explore the rationale behind combining agents targeting distinct pathophysiologic defects in T2DM.

Main Methods:

• Review of randomized double-blind clinical trials on sulfonylurea/metformin and metformin/rosiglitazone combination tablets.
• Analysis of efficacy, safety, glycemic control, and adherence associated with combination therapies.

Main Results:

• Fixed combination tablets (sulfonylurea/metformin) are safe and effective for drug-naive and treatment-experienced T2DM patients.
• Combination therapy may improve postprandial glycemic control but increases hypoglycemia risk, particularly in drug-naive individuals with HbA1c < 8.0%.
• Fixed-dose metformin/rosiglitazone offers a second-line option for T2DM patients not at glycemic goals with metformin monotherapy.

Conclusions:

• Combining agents with complementary mechanisms, such as insulin secretagogues/sensitizers or dual insulin sensitizers, enhances T2DM treatment efficacy.
• Fixed-dose combination tablets improve convenience and adherence but reduce administration flexibility.